Related Experiment Video

Updated: Aug 13, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery

Neil Thompson1, John Lyons

  • 1Astex Technology Ltd, 436 Cambridge Science Park, Milton Rd, Cambridge CB4 0QA, UK.

Current Opinion in Pharmacology
|June 16, 2005
PubMed

Insights

Activating Ras GTPase mutations drive many cancers, making the RAF/MEK/ERK pathway a key target for new cancer drugs. Promising molecularly targeted agents like BAY 43-9006 and PD0325901 are advancing in clinical trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Activating mutations in Ras GTPase are implicated in over 30% of human cancers.
  • The RAF/MEK/ERK signaling pathway is a critical regulator of cell proliferation and survival.
  • This pathway is frequently dysregulated in various malignancies, presenting a significant therapeutic target.

Purpose of the Study:

  • To review the significance of the RAF/MEK/ERK pathway in cancer development.
  • To highlight the progress of novel molecularly targeted anti-cancer agents targeting this pathway.
  • To discuss the therapeutic potential of BAY 43-9006 and PD0325901.

Main Methods:

  • Literature review of studies on Ras GTPase mutations and the RAF/MEK/ERK pathway.
  • Analysis of preclinical and clinical data for targeted anti-cancer agents.
  • Focus on agents in late-stage clinical development.

Main Results:

  • BAY 43-9006 and PD0325901 demonstrate significant promise in preclinical and early clinical studies.
  • These agents represent a new class of molecularly targeted therapies.
  • The RAF/MEK/ERK pathway is a validated target for anti-cancer drug development.

Conclusions:

  • Targeting the RAF/MEK/ERK pathway offers a promising strategy for cancer treatment.
  • BAY 43-9006 and PD0325901 are leading examples of effective targeted therapies.
  • Continued research and clinical development are crucial for realizing the full potential of these agents.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: